FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2552807584> ?p ?o ?g. }

• W2552807584 endingPage "2107" @default.
• W2552807584 startingPage "2107" @default.
• W2552807584 abstract "Abstract Background: Patients (pts) with refractory or relapsed and refractory multiple myeloma (RRMM) who have exhausted treatment (Tx) with lenalidomide (LEN) or thalidomide (THAL) and bortezomib (BORT) have shortened overall survival (OS; Kumar, Leukemia, 2012). Pomalidomide (POM) is a novel oral IMiDs® immunomodulatory agent with direct antimyeloma and stromal cell inhibitory effects (Quach, Leukemia, 2010; Mark, Leuk Res, 2014). POM 4 mg (± dexamethasone) is approved in some countries for Tx of pts with RRMM based on phase 3 results showing significant improvement vs high-dose dexamethasone in response, progression-free survival (PFS), and OS and phase 1/2 results showing high and durable overall response rates (ORRs; Richardson, Blood, 2013; Richardson, Blood, 2014; San Miguel, Lancet Oncol, 2013). MM-004 is a phase 1, open-label, dose-escalation study designed to assess the tolerated dose (TD), safety, efficacy, and pharmacokinetics (PK) of POM alone or POM + low-dose dexamethasone (LoDEX) in Japanese pts with RRMM. Methods: Pts must have been ≥ 20 yrs old with a documented diagnosis of MM, have had ≥ 2 prior lines of anti-MM Tx including ≥ 2 cycles of LEN and BORT (alone or in combination), and have RRMM defined as progressive disease (PD) during or within 60 days of completing their last anti-MM Tx. Tx consisted of POM 2 mg (Cohort 1) or 4 mg (Cohort 2) day (D) 1-21 of a 28-D cycle and DEX 40 mg (20 mg for pts > 75 yrs) D1, 8, 15, and 22 (starting on cycle 2). Tx was continued until PD, unacceptable adverse event (AE), or voluntary withdrawal. Pts enrolled in Cohort 1 received a single dose of POM 0.5 mg at D7 for PK evaluation. The primary endpoint was TD; secondary endpoints included ORR based on International Myeloma Working Group criteria, objective response, duration of response (DOR), PFS, PK, and safety. Results: Twelve pts were enrolled (6 in each cohort); 2 pts remain on Tx as of June 27, 2014 (Cohort 2, n= 2). Median age was 68 yrs (range, 52-76 yrs); 75% of pts were aged > 65 yrs. Median number of prior anti-MM Tx was 6 (range, 4-10) and baseline creatinine clearance (CrCl) was ≥ 60 mL/min for all pts except one. Six pts received prior THAL-based Tx (Cohort 1, n= 3; Cohort 2, n= 3). TD was determined to be POM 4 mg D1-21 of a 28-D cycle (a dose-limiting toxicity of grade 4 neutropenia for ≥ 7 days was observed in 1 pt in cohort 1). This result showed that the TD of POM in Japanese pts with MM was the same as that in Caucasian pts with MM. Median duration of treatment was 6.5 cycles in all pts. The best ORR (≥ partial response [PR]) was 25% (3/12 pts) across both cohorts; ORR was 17% (1/6) in Cohort 1 and 33% (2/6) in Cohort 2. Overall median PFS was 5.5 months (5.1 months in Cohort 1; not reached in Cohort 2). Maximum POM plasma concentration (Cmax) was 9.1, 35.6, and 70.2 ng/mL after single dose of POM 0.5, 2, and 4 mg, respectively, and was reached at times ranging from 0.9 to 6 h. Cmax was 37.6 and 71.2 ng/mL after multiple doses of POM 2 and 4 mg. Systemic POM exposure as measured by geometric means of area under the plasma concentration time curve (AUC) was 84.9, 364.4, and 685.7 ng•h /mL after a single doses of POM 0.5, 2, and 4 mg, respectively. AUC was 411.5 and 713.8 ng•h /mL after multiple doses of POM 2 mg and 4 mg. Both Cmax and AUC exposures increased in a dose-proportional manner from 0.5 to 4 mg, as assessed by both visual inspection and statistical analysis. Clearance and volume of distribution were similar across dose levels. The mean half-life (t1/2) of POM was comparable across dose levels, with t1/2 of approximately 6.4, 6.9, and 6 h after single doses of POM 0.5, 2, and 4 mg, respectively. After multiple doses of POM 2 mg and 4 mg, t1/2was approximately 7.3 and 5.5 h. Grade ≥ 3 AEs occurred in 11 pts (92%), and the most frequently reported AE was neutropenia (8 pts, 67%). Other frequently reported AEs (all grades) were thrombocytopenia, anemia, leukopenia, and peripheral edema. Conclusions: POM 4 mg was identified as the TD in Japanese pts with RRMM, which is consistent with previous findings in Caucasian pts with MM. However, pts should be monitored for the known AE profile of POM and managed appropriately. The combination of POM with LoDEX was also found to be tolerable in Japanese pts with RRMM. Systemic exposure to POM increased dose proportionally, and limited drug accumulation was observed following multiple doses. Responses (≥ PR) were observed in 25% of pts. Further investigation of the efficacy and safety of POM + LoDEX in Japanese pts with RRMM in a phase 2 trial is warranted. Disclosures Iida: Celgene Corp: Honoraria, Research Funding. Tobonai:Ono: Research Funding; Lilly: Research Funding; Janssen: Research Funding; Celgene Corporation: Research Funding. Sunami:Celgene Corp: Honoraria. Kurihara:Celgene Corporation: Employment. Midorikawa:Celgene: Employment. Zaki:Celgene : Employment, Equity Ownership. Doerr:Celgene Corp: Employment." @default.
• W2552807584 created "2016-11-30" @default.
• W2552807584 creator A5018851305 @default.
• W2552807584 creator A5025340212 @default.
• W2552807584 creator A5032373476 @default.
• W2552807584 creator A5041678137 @default.
• W2552807584 creator A5055360788 @default.
• W2552807584 creator A5057175176 @default.
• W2552807584 creator A5060126327 @default.
• W2552807584 creator A5066198298 @default.
• W2552807584 creator A5066881350 @default.
• W2552807584 creator A5078852881 @default.
• W2552807584 creator A5081439101 @default.
• W2552807584 date "2014-12-06" @default.
• W2552807584 modified "2023-09-27" @default.
• W2552807584 title "MM-004: A Phase 1, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, Efficacy, and Pharmacokinetics of Pomalidomide Alone or in Combination with Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma in Japan" @default.
• W2552807584 doi "https://doi.org/10.1182/blood.v124.21.2107.2107" @default.
• W2552807584 hasPublicationYear "2014" @default.
• W2552807584 type Work @default.
• W2552807584 sameAs 2552807584 @default.
• W2552807584 citedByCount "0" @default.
• W2552807584 crossrefType "journal-article" @default.
• W2552807584 hasAuthorship W2552807584A5018851305 @default.
• W2552807584 hasAuthorship W2552807584A5025340212 @default.
• W2552807584 hasAuthorship W2552807584A5032373476 @default.
• W2552807584 hasAuthorship W2552807584A5041678137 @default.
• W2552807584 hasAuthorship W2552807584A5055360788 @default.
• W2552807584 hasAuthorship W2552807584A5057175176 @default.
• W2552807584 hasAuthorship W2552807584A5060126327 @default.
• W2552807584 hasAuthorship W2552807584A5066198298 @default.
• W2552807584 hasAuthorship W2552807584A5066881350 @default.
• W2552807584 hasAuthorship W2552807584A5078852881 @default.
• W2552807584 hasAuthorship W2552807584A5081439101 @default.
• W2552807584 hasConcept C112705442 @default.
• W2552807584 hasConcept C121332964 @default.
• W2552807584 hasConcept C126322002 @default.
• W2552807584 hasConcept C126894567 @default.
• W2552807584 hasConcept C142424586 @default.
• W2552807584 hasConcept C143998085 @default.
• W2552807584 hasConcept C2776063141 @default.
• W2552807584 hasConcept C2776364478 @default.
• W2552807584 hasConcept C2776694085 @default.
• W2552807584 hasConcept C2777063308 @default.
• W2552807584 hasConcept C2777478702 @default.
• W2552807584 hasConcept C2778524551 @default.
• W2552807584 hasConcept C2778822529 @default.
• W2552807584 hasConcept C2779609412 @default.
• W2552807584 hasConcept C2780401358 @default.
• W2552807584 hasConcept C29730261 @default.
• W2552807584 hasConcept C31760486 @default.
• W2552807584 hasConcept C71924100 @default.
• W2552807584 hasConcept C87355193 @default.
• W2552807584 hasConcept C90924648 @default.
• W2552807584 hasConcept C98274493 @default.
• W2552807584 hasConceptScore W2552807584C112705442 @default.
• W2552807584 hasConceptScore W2552807584C121332964 @default.
• W2552807584 hasConceptScore W2552807584C126322002 @default.
• W2552807584 hasConceptScore W2552807584C126894567 @default.
• W2552807584 hasConceptScore W2552807584C142424586 @default.
• W2552807584 hasConceptScore W2552807584C143998085 @default.
• W2552807584 hasConceptScore W2552807584C2776063141 @default.
• W2552807584 hasConceptScore W2552807584C2776364478 @default.
• W2552807584 hasConceptScore W2552807584C2776694085 @default.
• W2552807584 hasConceptScore W2552807584C2777063308 @default.
• W2552807584 hasConceptScore W2552807584C2777478702 @default.
• W2552807584 hasConceptScore W2552807584C2778524551 @default.
• W2552807584 hasConceptScore W2552807584C2778822529 @default.
• W2552807584 hasConceptScore W2552807584C2779609412 @default.
• W2552807584 hasConceptScore W2552807584C2780401358 @default.
• W2552807584 hasConceptScore W2552807584C29730261 @default.
• W2552807584 hasConceptScore W2552807584C31760486 @default.
• W2552807584 hasConceptScore W2552807584C71924100 @default.
• W2552807584 hasConceptScore W2552807584C87355193 @default.
• W2552807584 hasConceptScore W2552807584C90924648 @default.
• W2552807584 hasConceptScore W2552807584C98274493 @default.
• W2552807584 hasIssue "21" @default.
• W2552807584 hasLocation W25528075841 @default.
• W2552807584 hasOpenAccess W2552807584 @default.
• W2552807584 hasPrimaryLocation W25528075841 @default.
• W2552807584 hasRelatedWork W2039196526 @default.
• W2552807584 hasRelatedWork W2111732928 @default.
• W2552807584 hasRelatedWork W2128903704 @default.
• W2552807584 hasRelatedWork W2136541422 @default.
• W2552807584 hasRelatedWork W2275604345 @default.
• W2552807584 hasRelatedWork W2576841436 @default.
• W2552807584 hasRelatedWork W2578386045 @default.
• W2552807584 hasRelatedWork W2768247688 @default.
• W2552807584 hasRelatedWork W2980039687 @default.
• W2552807584 hasRelatedWork W3007230085 @default.
• W2552807584 hasVolume "124" @default.
• W2552807584 isParatext "false" @default.
• W2552807584 isRetracted "false" @default.
• W2552807584 magId "2552807584" @default.
• W2552807584 workType "article" @default.